Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
In what situations would you consider doublet chemotherapy in treatment of a premenopausal de novo metastatic TNBC?
Related Questions
What is your experience and treatment efficacy of tucatinib if used after enhertu in metastatic breast cancer?
Would you use elacestrant in a patient with an ESR1-AKAP12 fusion?
Are there any scenarios you would use CDK 4/6i to treat HR-positive HER2-positive breast cancer in combination with anti-HER2 agents?
How do you treat metastatic adenoid cystic carcinoma of breast primary, ER 3%, PR, HER 2 negative with liver only metastasis?
Do you routinely check echocardiograms on all patients who are starting TDM1?
How do you monitor blood glucose levels in patients without preexisting diabetes who are starting capivasertib?
Are there scenarios where you would consider use of capivasertib for non-AKT pathway altered patients given the efficacy seen in the overall treatment population of the CAPItello-291 trial?
How reliable is the liquid biopsy on patients with progressing HER2 positive breast cancer with negative HER2 on liquid testing?
Do you start systemic therapy for patients with previously localized HR+ breast cancer developing solitary bone metastasis which is now triple negative if there are no other sites of disease after metastasis-directed radiation?
In what circumstance, if any, would you consider fulvestrant + capivasertib over CDK4/6 inhibitors in a patient who has HR+, PIK3CA mutant metastatic breast cancer?
